38 träffarStandard & Latin

Lampa som drivs av saltvatten eller urin – Salt Tech vinner familjen Spendrups stipendium för sin unika innovation19.3.2025 12:27:31 CET | Spendrups Bryggeri AB | Pressmeddelande

Familjen Spendrup vill uppmuntra och stödja unga entreprenörer i Sverige genom ett årligt återkommande stipendium som har delats ut till tidigare UF-elever sedan 2008. I år går stipendiet till William Asefaw som driver Salt Tech. Företaget har en unik lösning med en lampa som drivs av saltvatten eller urin – som en av lösningarna på elfattigdomen i världen.
news aktuell GmbH

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist22.10.2024 13:11:31 CEST | news aktuell GmbH | Pressmeddelande

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as pot
news aktuell GmbH

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients.17.7.2024 09:52:50 CEST | news aktuell GmbH | Press Release

Investment of more than €80 million to modernise Latin American production sites. In Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually. In Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.
news aktuell GmbH

How to halt democracy erosion19.3.2024 08:00:00 CET | news aktuell GmbH | Press Release

The quality of democracy in developing and transformation countries has been in steady decline over the past 20 years. The latest findings of the Transformation Index of the Bertelsmann Stiftung, now in its tenth edition, show that out of 137 countries surveyed, only 63 remain democracies, while a majority are classified as autocracies. However, there is reason for hope. The examples of the transformation countries Brazil and Poland, where voters have rebuffed authoritarian trends, show the potential for reversing democratic erosion.
news aktuell GmbH

Grünenthal acquires testosterone treatment NebidoTM from Bayer14.7.2022 08:24:23 CEST | news aktuell GmbH | Press Release

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability. Aachen, Germany, 14 July 2022 –Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The bra
Jernkontoret

Timmermans efterfrågar snabba tillståndsprocesser men mångdubblar kraven i industriutsläppsdirektivet IED6.4.2022 10:11:39 CEST | Jernkontoret | Pressmeddelande

EU-kommissionen har nu presenterat sitt förslag till nytt industriutsläppsdirektiv (IED). I förslaget föreslår kommissionen att många nya parametrar ska regleras i tillstånden, något som riskerar innebära en svår belastning på många svenska företag. Jernkontorets forskningschef Eva Blixt, en av få svenska IED-experter, pekar på en överhängande risk för ett IED 2.0 som begränsar företagens möjlighet för att skapa tillväxt, konkurrenskraft och inte minst förutsättningar för att fortsätta ställa om till mer hållbar produktion.
  • 1
  • 2
  • Sista
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye